/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSMEMINATION IN THE UNITED STATES/
BOUCHERVILLE, QC, Dec. 17, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (The "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce that it has entered into an arm's length letter of intent dated December 16, 2025 (the "Agreement") with Juno Pharmaceuticals LP (the "Seller"), to acquire (the "Acquisition") all of the outstanding shares of Juno OTC Inc. ("Juno OTC"), a Toronto based wholly owned subsidiary of the Seller, for a total purchase price of $5 million (the "Purchase Price") to be paid to the Seller. As set forth in the Agreement, the Purchase Price will be paid as follows: (i) $2,500,000 in cash on the closing date of the Acquisition (the "Acquisition Closing Date"); (ii) such number of Class "A" common shares of the Corporation (the "Common Shares") on the Acquisition Closing Date as is equal to $2,000,000 divided by the volume-weighted average price of the Common Shares for the twenty (20) consecutive trading days preceding the execution of the definitive share purchase agreement; and (iii) $500,000 in cash on January 1, 2027 (the "Purchase Price Balance"). The Purchase Price Balance of $500,000 payable on January 1, 2027 will be adjusted to reflect variations in working capital, if any.
Read more at newswire.ca